Home » Stocks » DECI

Decipher Biosciences, Inc. (DECI)

Decipher Biosciences will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Market Cap n/a
Revenue (ttm) 33.26M
Net Income (ttm) -5.83M
Shares Out n/a
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day n/a
Last Price n/a
Previous Close n/a
Change ($) n/a
Change (%) n/a
Day's Open n/a
Day's Range n/a
Day's Volume n/a
52-Week Range n/a

News

Hide News

Decipher Biosciences, which provides genomic testing products for urologic oncology, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering.

3 months ago - NASDAQ

Decipher Biosciences, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

About DECI

Decipher Biosciences is a commercial-stage precision oncology company committed to improving patient care, with a focus in urologic oncology specific to prostate and bladder cancers. Our novel prostate cancer genomic testing products, Decipher Biopsy and Decipher RP, provide valuable information about the underlying biology of a patient’s tumor, assisting physicians in their selection of an optimal therapy. Our differentiated approach measures the biological activity of a patient’s entire tumor genome, known as whole transcriptome analysis,... [Read more...]

Industry
Medical Devices
IPO Date
Pending
CEO
Tina S. Nova, Ph.D.
Employees
95
Stock Exchange
NASDAQ
Ticker Symbol
DECI
Full Company Profile

Financial Performance

In 2019, DECI's revenue was $16.52 million, an increase of 36.89% compared to the previous year's $12.07 million. Losses were -$18.45 million, -38.37% less than in 2018.

Financial Statements